How Darolutamide’s Safety Profile in nmCRPC Differs from Similar Agents
Patrick G. Pilié, MD, explains how the safety profile of darolutamide, as seen in the ARAMIS clinical trial, differs from those of enzalutamide and apalutamide.
Patrick G. Pilié, MD, an assistant professor of the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas, explains how the safety profile of darolutamide (Nubeqa), as seen in the ARAMIS clinical trial (NCT02200614), differs from those of enzalutamide (Xtandi) and apalutamide (Erleada), as evaluated in the PROPSER (NCT02003924) and SPARTAN (NCT01946204) clinical trials.
In the all 3 randomized phase 3 trials, the antiandrogen agents showed improvement metastasis-free survival and overall survival (OS) in patient, and Pilié says that the results are both biologically and clinical reassuring. In ARAMIS, in particular, the OS benefit was a 31% reduction in the risk of death. Aside from OS, the unique feature about darolutamide is the safety profile, explains Pilié.
In comparison to what was observed with enzalutamide and apalutamide, data from darolutamide showed less of a increased risk for fracture, hypertension, cognitive impairment, and seizures.
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
January 2nd 2025The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
